Neuromuscular

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 23, 2024.

The professor in the Department of Translational Neuroscience at Barrow Neurological Institute provided perspective on the approval of tofersen (Qalsody; Biogen) for patients with ALS and the ways neurofilament light will be used going forward. [WATCH TIME: 3 minutes]

A recent phase 3 trial demonstrated that N-acetyl-l-leucine significantly improved symptoms in patients with Niemann-Pick disease type C, showing promise as a potential treatment.

A recent observational study detected anti-DLAT antibodies in the serum of patients with chronic inflammatory demyelinating polyneuropathy with a sensory-dominant phenotype.

After a positive phase 1 study, DNL788, an RIPK1 inhibitor, failed to distinguish itself from placebo in HIMALAYA.

The associate professor of neurology at Columbia University talked about a track session that he will be chairing at the upcoming MDA conference on amyotrophic lateral sclerosis genetic research. [WATCH TIME: 5 minutes]

The professor in the Department of Translational Neuroscience at Barrow Neurological Institute discussed several topics related to ALS research and the emerging biomarkers in recent years ahead of the 2024 MDA Clinical and Scientific Conference.

A recent review of studies indicated that intravenous immunoglobulin could be as effective as other treatments in improving disability for patients with chronic inflammatory demyelinating polyradiculoneuropathy.

IVIg and SCIg exhibit differing effects on cytokine profiles in CIDP, potentially due to their distinct pharmacokinetics.

The professor in the Department of Translational Neuroscience at Barrow Neurological Institute provided comments on her session track at the upcoming 2024 MDA conference and some of the recent advancements in ALS research. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Neurology News Network for the week ending February 17, 2024. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 16, 2024.

The FDA has accepted Sarepta Therapeutics' efficacy supplement for gene therapy SRP-9001, granting it a priority review for the treatment of Duchenne muscular dystrophy, with a decision expected by June 21, 2024.

Experts from different subspecialties in neurology shared their clinical perspectives for patients on promising therapeutics and expansion of care interventions for 2024.

The efficacy of vamorolone at a dose of 6 mg/kg/d was maintained over 48 weeks of treatment for all 5 motor outcomes.

Omaveloxolone is an oral, once-daily medication indicated for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older in both the United States and the European Union.

The postdoctoral research fellow at Brigham and Women’s Hospital and Harvard Medical School discussed some of the issues with ensuring timely care access to approved therapies for patients with Duchenne muscular dystrophy. [WATCH TIME: 3 minutes]

Ahead of the 2024 MDA Conference, the medical advisor and care center director at Muscular Dystrophy Association talked about the track sessions he will be cochairing at the meeting. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders, and specifically, Duchenne muscular dystrophy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 9, 2024.

The postdoctoral research fellow at Brigham and Women’s Hospital and Harvard Medical School provided answers to a recently published study highlighting the burden of care and infrequent use of novel exon-skipping drugs for Duchenne in clinical settings. [WATCH TIME: 3 minutes]

The chief executive officer of ClearPoint Neuro provided clarity on how the recently approved SmartFrame system can enhance the efficiency of operating room procedures, allowing for flexible workflows and image-based corrections.

The promising results of nipocalimab in pivotal studies suggest a potential breakthrough in treating autoimmune diseases like generalized myasthenia gravis and Sjögren’s.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke.

Neurology News Network for the week ending February 3, 2024. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 2, 2024.